A woman who has plans to get pregnant has been taking captopril to manage her hypertension. Which statement made by the nurse is most appropriate when addressing taking this medication?

A. "Continuing captopril during pregnancy will not pose any risks to the developing fetus.": Captopril is an ACE inhibitor and is contraindicated in pregnancy due to its high risk of causing fetal malformations, renal failure, or death. Continuing the drug during pregnancy is unsafe and can lead to serious fetal harm. B. "Switching to another ACE inhibitor is advisable to reduce the risk of teratogenic effects during pregnancy.": All ACE inhibitors carry similar teratogenic risks. Switching to another ACE inhibitor does not eliminate fetal risk. An alternative antihypertensive from a safer class is required. C. "It is safe to take captopril during the first trimester as the teratogenic effects only occur later in pregnancy.": Teratogenic effects of ACE inhibitors can occur in any trimester, especially affecting fetal renal development in the second and third trimesters. First-trimester exposure can also cause congenital malformations. Use during any stage is unsafe. D. "Captopril should be discontinued and replaced with an alternative to avoid teratogenic effects on the fetus": Discontinuing captopril before pregnancy and using a safer antihypertensive (e.g., labetalol or methyldopa) reduces the risk of fetal malformations and adverse pregnancy outcomes. Patient education on medication adjustment prior to conception is essential for safety.